New CAR-T therapy achieved complete remission in 70% of aggressive cancer patients
CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with remission rates reaching as high as 90%. This therapy modifies a patient’s T cells to recognize and destroy cancer cells.
New CAR-T cell therapy shows promise for hard-to-treat cancers
Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder for prior CAR-T therapies to detect and fight.
Overcoming CAR T-Cell Therapy Limitations
In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and innovative manufacturing strategies are overcoming the key limitations of autologous CAR T-cell therapy.
Supercharged T-Cells Hunt Down the Hardest-to-Treat Cancers
Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape detection. This innovation, called ALA-CART, helps the immune system better recognize and destroy resistant cancers.
A child who got CAR-T cancer therapy is still disease-free 18 years later
The long-term survival of a patient with neuroblastoma suggests the personalized cancer treatment may work for solid tumors, not just blood cancers.
Next-Generation CAR T-Cell Therapy Designed for Hard-To-Treat Cancers
Researchers at the University of Colorado Anschutz Medical Campus have successfully developed an iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against hard-to-treat cancer cells.
New CAR-T cell therapy 'ALA-CART' shows promise for hard-to-treat cancers
Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells,
US researchers develop next-gen CAR-T therapy to kill hard-to-treat cancers
CART, a next-gen CAR-T therapy for improved targeting and functionality to address this. “ALA-CART improves the ability of CAR-T cells
Luminary Therapeutics to Develop Allogeneic CAR T Therapy for Targeting Solid Tumors
Luminary Therapeutics today announced that it has been awarded up to $5.8 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of ...
Xenetic presents preclinical data on DNase I with CAR T cells in murine model
Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...
What Vanderbilt-Ingram Cancer Center's 'sci-fi' therapy means for this grateful TN dad
This cancer-patient dad of three young kids is grateful for a "sci-fi" blood treatment advanced by Vanderbilt and oncologist Dr. Olalekan Oluwole.
CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...